RAPIVAB® (peramivir injection)
This BioCryst-discovered drug is used for the treatment of influenza.
In December 2014, RAPIVAB® was approved by the FDA, the first FDA approval of a drug discovered by BioCryst.
RAPIVAB® is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
For additional information, please visit www.RAPIVAB.com, and for full U.S. prescribing information, click here.
RAPIVAB® is a registered trademark of BioCryst Pharmaceuticals, Inc. or its affiliates.